Shares of Arcutis Biotherapeutics Inc. (ARQT) have nearly doubled in value over the past year, thanks to the success of its flagship product ZORYVE, which has been developed as a portfolio of innovative topical therapies that is redefining the treatment of chronic inflammatory skin diseases and demonstrating strong, sustainable commercial momentum across all strengths and indications.
ZORYVE is a next-generation small molecule inhibitor of phosphodiesterase-4 (PDE4) that has been implicated in a wide range of inflammatory diseases. It is available in cream and foam formulations at multiple strengths, has been approved for several indications, and is being explored for further uses.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.